TLRY - Tilray, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
21.25
-0.32 (-1.48%)
As of 1:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous close21.57
Open21.26
Bid21.30 x 900
Ask21.33 x 800
Day's range20.92 - 22.16
52-week range20.20 - 120.40
Volume1,892,991
Avg. volume1,862,436
Market cap2.136B
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.54
Earnings date12 Nov 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est35.08
  • Bloomberg

    Tilray Canada Business to Turn Profit Ahead of Target, CEO Says

    (Bloomberg) -- Tilray Inc.’s Canadian operations should be profitable sooner than the late 2020 target set for the company as a whole, according to Chief Executive Officer Brendan Kennedy.The cannabis company said Tuesday that it expects to generate overall positive earnings before interest, taxes, depreciation and amortization by the final quarter of next year. However, Kennedy said its primary Canadian business should reach the key metric sooner than that.“It’s likely that our business in Canada will be Ebitda positive before the rest of our business, just because it’s at a different stage of development,” he said Wednesday in an interview with Bloomberg TV on the sidelines of Cowen & Co.’s cannabis conference in Boston. “That business is much more mature. We’ve been operating it for six years.” Once-bullish investors have increasingly punished cannabis companies that don’t show a clear path to profitability. Tilray’s shares have fallen about 70% since the beginning of the year amid broad-based weakness across the sector. The stock was also volatile on Wednesday after the company posted a wider-than-expected Ebitda loss.Management’s optimistic forecasts have been thwarted due to a slower-than-expected retail rollout in Canada and regulatory issues in the U.S., but Kennedy said he’s confident that Tilray will meet its guidance, which assumes 800 to 1,000 stores open by the end of 2020.“We have some buffer in our targets,” he said. “That gives us a lot of confidence.”Tilray also said it has enough cash to fund its operations until it reaches positive Ebitda in late 2020, but Kennedy said it has options if it does need to raise capital.“We have about $300 million in real estate and facility assets that we own completely, so that’s clearly one option,” he said. “But at this point we haven’t moved very far down any of those paths.”To contact the reporter on this story: Kristine Owram in New York at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Tilray, Inc. (TLRY) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Tilray, Inc. (TLRY) Reports Q3 Loss, Tops Revenue Estimates

    Tilray, Inc. (TLRY) delivered earnings and revenue surprises of -72.41% and 3.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • 5 Trendy Earnings Charts
    Zacks

    5 Trendy Earnings Charts

    Are cannabis and solar stocks still the place to be for traders in 2019?

  • Investing.com

    Day Ahead: Top 3 Things to Watch

    Investing.com - Here is a preview of the top 3 things that could rock markets tomorrow.

  • Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
    Zacks

    Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

    Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

  • Powell heads to Capitol Hill, Trump speaks in NY — What to know in the week ahead
    Yahoo Finance

    Powell heads to Capitol Hill, Trump speaks in NY — What to know in the week ahead

    Federal Reserve Chairman Jerome Powell and President Donald Trump will take centerstage this week.

  • CBD beverage founder: 'I want to be regulated'
    Yahoo Finance

    CBD beverage founder: 'I want to be regulated'

    Not nearly enough legislative ink has been spilled over the booming CBD industry, according to Benjamin Witte. 

  • Tilray (TLRY) Set to Report Q3 Results: Will the Stock Continue to Plunge?
    Zacks

    Tilray (TLRY) Set to Report Q3 Results: Will the Stock Continue to Plunge?

    Tilray (TLRY) is set to report its third quarter results after the closing bell Tuesday, November 12.

  • Pay Attention to Hard to Borrow Rates, Even in Options Trades
    Zacks

    Pay Attention to Hard to Borrow Rates, Even in Options Trades

    Pay Attention to Hard to Borrow Rates, Even in Options Trades

  • GlobeNewswire

    IntelGenx Reports Third Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Nov. 07, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.

  • U.S.-China Trade Progress, Q3 Earnings Results & Buy Yeti Stock - Free Lunch
    Zacks

    U.S.-China Trade Progress, Q3 Earnings Results & Buy Yeti Stock - Free Lunch

    The latest U.S.-China trade war news that could see the world's two largest economies roll back tariffs. Q3 earnings results from the likes of Qualcomm and Square. And why Yeti is a Zacks Rank 1 (Strong Buy) stock...

  • Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

    Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.

  • Former Canopy Growth CEO Bruce Linton joins US cannabis company's board, Vireo stock surges 35%
    Yahoo Finance

    Former Canopy Growth CEO Bruce Linton joins US cannabis company's board, Vireo stock surges 35%

    After parting ways with Canadian cannabis giant Canopy Growth, Bruce Linton is joining the board of U.S. multi-state operator Vireo Health.

  • Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?
    Zacks

    Buy Cronos (CRON) Stock Ahead of Earnings as Bet on Marijuana Comeback?

    Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?

  • The CBD 'floodgate has opened' for pro athletes: Olympian Lolo Jones
    Yahoo Finance

    The CBD 'floodgate has opened' for pro athletes: Olympian Lolo Jones

    Olympic hurdler and bobsledder Lolo Jones joins an extremely long list of athletes now pumping CBD brands.

  • 4 Highly-Ranked Cheap Stocks Trading Under $10 to Buy Right Now
    Zacks

    4 Highly-Ranked Cheap Stocks Trading Under $10 to Buy Right Now

    Today we highlighted 4 'cheap' stocks that are currently trading for under $10 per share that also sport a Zacks Rank 2 (Buy) or better that investors might want to consider buying right now...

  • Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
    Zacks

    Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know

    Tilray, Inc. (TLRY) closed at $22.43 in the latest trading session, marking a +1.49% move from the prior day.

  • Tilray, Inc. (TLRY) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Tilray, Inc. (TLRY) Expected to Beat Earnings Estimates: Should You Buy?

    Tilray, Inc. (TLRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CBD is ‘the caffeine of the 21st century’: Recess CEO
    Yahoo Finance

    CBD is ‘the caffeine of the 21st century’: Recess CEO

    The key to selling a CBD product is to not sell the CBD, according to Benjamin Witte.

  • Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
    Zacks

    Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know

    Tilray, Inc. (TLRY) closed the most recent trading day at $22.21, moving +0.27% from the previous trading session.

  • 5 Top-Ranked Cheap Stocks Trading Under $20 to Buy Right Now
    Zacks

    5 Top-Ranked Cheap Stocks Trading Under $20 to Buy Right Now

    Today we found 5 cheap stocks currently trading for under $20 per share using our Zacks Stock Screener that investors might want to buy heading into November...

  • Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
    Zacks

    Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?

    Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.

  • Tilray Jumps on Study of Cannabis for Breast Cancer Side Effects
    Bloomberg

    Tilray Jumps on Study of Cannabis for Breast Cancer Side Effects

    (Bloomberg) -- Tilray Inc. shares jumped as much as 14% after announcing it successfully imported medical cannabis into the U.S. in support of a clinical trial studying its efficacy in treating patients with disorders caused by breast cancer treatments.The study will focus on patients suffering from taxane-induced peripheral neuropathy, or TIPN, secondary to treatment with paclitaxel or docetaxel. TIPN affects more than 67% of women undergoing breast cancer treatment, the company said.“Tilray is committed to advancing cannabis research through its support of clinical trials around the world as we continue to enhance our understanding of the potential benefits of medical cannabis,” Philippe Lucas, vice president of global patient research and access, said in a statement.Tilray shares were trading around $24.87 at 3:25 p.m. in New York, down 65% since the start of the year.To contact the reporter on this story: Gregory Calderone in New York at gcalderone7@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jeran WittensteinFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • E-Cigarette Ban in New York: Impact on Cannabis Sector
    Market Realist

    E-Cigarette Ban in New York: Impact on Cannabis Sector

    The vaping crisis has brought on some twists and turns for the cannabis sector. New York courts are now weighing an e-cigarette ban.

  • Pot stocks ‘significantly oversold’: ETF manager
    Yahoo Finance

    Pot stocks ‘significantly oversold’: ETF manager

    Legal pot could provide "significant upside" for investors, ETF manager says